In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and ...
Eli Lilly built up $1.5 billion in pre-launch inventory for its experimental oral weight-loss drug orforglipron, according to a regulatory filing.
PTC Therapeutics withdrew its New Drug Application (NDA) resubmission for Translarna (ataluren) in nonsense mutation Duchenne muscular dystrophy (nmDMD) following feedback from FDA indicating that the ...
Kim Boericke, CEO, Veristat, discusses how Veristat is adapting clinical trials by using data, AI, and operational planning to optimize site selection, manage complex cell and gene therapy logistics, ...
The CEO of TransCelerate BioPharma Inc. She has been part of the organization since its inception in 2012 and has more than 20 years of experience leading initiatives in large pharma and biotech ...
To be successful in the pharmaceutical industry, leaders must be willing to take risks. During his conversation with Pharmaceutical Executive, Leonard Mazur kept coming back to this point. According ...
In a conversation with Pharmaceutical Executive, Phesi founder and CEO Gen Li discusses his company’s recent global analysis of clinical trials. While the report once again showed that breast cancer ...
Bridging the Data Gap: How Digital Behavioral Insights Can Transform HCP Targeting in Specialty Care
Taking the targeting of oncologists likely to start treatment with CAR-T as an example, validation studies show that targeting top-scored physicians from predictive models yields precision rates of 60 ...
Wang, who led AstraZeneca’s China operations for roughly a decade, was detained back in 2024, with his arrest triggering a sharp sell-off in AstraZeneca shares at the time, amid broader investigations ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
Yerem Yeghiazarians founder, CEO of Soley Therapeutics, talks about how drug discovery is a team effort, noting that success ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results